Nifty Trading for the day:
As we stand by our call to go long on Nifty from 8550 to 8700 levels ( Spot Levels ). Nifty has broke out above that levels in last hour of buying and closed well above that ( 8744 ). We recommend to hold long positions with a revised stop loss of 8700 ( Spot Levels ). Also new entry can be made at or around these levels. Now onwards intraday gains might not possible. So take a view for 2-3 trading sessions.
FII & DII combined bought more than 800 cr in cash segment, while FII bought 2100 cr in Index futures. These suggest going long at these levels as well. Don't go short at these levels, instead buy on every dip.
View our previous recommendation here
As we stand by our call to go long on Nifty from 8550 to 8700 levels ( Spot Levels ). Nifty has broke out above that levels in last hour of buying and closed well above that ( 8744 ). We recommend to hold long positions with a revised stop loss of 8700 ( Spot Levels ). Also new entry can be made at or around these levels. Now onwards intraday gains might not possible. So take a view for 2-3 trading sessions.
FII & DII combined bought more than 800 cr in cash segment, while FII bought 2100 cr in Index futures. These suggest going long at these levels as well. Don't go short at these levels, instead buy on every dip.
View our previous recommendation here
Nifty Outlook For 30 August 2016
As we have predicted that US Fed's Chair Janet Yellen's comment about possible rate hike in September wouldn't be market moving and end up as non event, as most asian markets have consolidated throughout the day, except Nikkei, which was up more than 2%, thanks to the BoJ's comments about more stimulus. ( 29th August, Monday ).
Read Our Previous Comments Here.
Nifty Trading For 30 August 2016
For Traders, We recommended buy on dips strategy yesterday, rather than going short, which worked almost perfectly as Nifty has bounced back from 8550 levels and closed above 8600, as last hour rally, led by heavyweight Reliance, helped to stay above 8600. We will continue to hold long positions in Nifty with a stop loss of 8550 with a target of 8680-8700 ( Spot levels ).
For new positions, we would recommend only at 8600 spot levels, would be a stop loss with a target of 8680-8700. If you don't get a chance to enter at 8600, you can make an entry below 8630 levels, don't buy Nifty above 8650, as the levels are not favourable for risk reward.
As we have predicted that US Fed's Chair Janet Yellen's comment about possible rate hike in September wouldn't be market moving and end up as non event, as most asian markets have consolidated throughout the day, except Nikkei, which was up more than 2%, thanks to the BoJ's comments about more stimulus. ( 29th August, Monday ).
Read Our Previous Comments Here.
Nifty Trading For 30 August 2016
For Traders, We recommended buy on dips strategy yesterday, rather than going short, which worked almost perfectly as Nifty has bounced back from 8550 levels and closed above 8600, as last hour rally, led by heavyweight Reliance, helped to stay above 8600. We will continue to hold long positions in Nifty with a stop loss of 8550 with a target of 8680-8700 ( Spot levels ).
For new positions, we would recommend only at 8600 spot levels, would be a stop loss with a target of 8680-8700. If you don't get a chance to enter at 8600, you can make an entry below 8630 levels, don't buy Nifty above 8650, as the levels are not favourable for risk reward.
Nifty Outlook:
Finally Nifty has broken the 8600-8680 range on the lower side and closed at 8592. Profit booking was seen in Bank Nifty as well. The noticeable thing is FII were net buyers in index futures of more than 1000 cr and cash market of more than 300 cr, which helped index from deeper cut. Also, US fed commentary on friday at Jackson Hole, Wyoming was nothing more than confusing. It has reignited a fear of rate hike in September, which might trigger an outflow from Ems ( Emerging markets ).
1) For Investors, Who are waiting on sidelines.
Start focusing on your buy list and pick them slowly. Don't worry if markets headed south. Just keep buying.
2) For traders, Apply buy on dips strategy but be cautious as 8500 levels on Nifty might not stay due to US fed rate hike prospect. Focus on dollar index, gold and US treasury, to get idea of strength or weakness in Nifty. 8450-8480 will be a good zone to buy for target of 8620. Don't go short, as FII are still buying every dip, means liquidity will trap you. Also, if Nifty doesn't dip more, then no trade left Nifty above 8620-8640 levels.
Finally Nifty has broken the 8600-8680 range on the lower side and closed at 8592. Profit booking was seen in Bank Nifty as well. The noticeable thing is FII were net buyers in index futures of more than 1000 cr and cash market of more than 300 cr, which helped index from deeper cut. Also, US fed commentary on friday at Jackson Hole, Wyoming was nothing more than confusing. It has reignited a fear of rate hike in September, which might trigger an outflow from Ems ( Emerging markets ).
1) For Investors, Who are waiting on sidelines.
Start focusing on your buy list and pick them slowly. Don't worry if markets headed south. Just keep buying.
2) For traders, Apply buy on dips strategy but be cautious as 8500 levels on Nifty might not stay due to US fed rate hike prospect. Focus on dollar index, gold and US treasury, to get idea of strength or weakness in Nifty. 8450-8480 will be a good zone to buy for target of 8620. Don't go short, as FII are still buying every dip, means liquidity will trap you. Also, if Nifty doesn't dip more, then no trade left Nifty above 8620-8640 levels.
"WEALTH MANTRA"
If you "RISK" Nothing, You "RISK" Everything...
"WEALTH CREATION" is an "ART", approach a "WEALTH CREATOR" for better "RETURNS"...
3 of 3 Photo(s)
If you "RISK" Nothing, You "RISK" Everything...
"WEALTH CREATION" is an "ART", approach a "WEALTH CREATOR" for better "RETURNS"...
3 of 3 Photo(s)
The selling in Facebook stock is partly due to the end of lock up period for 270 million shares, that could hit the market over the period of nine months. Read More
Hidden Gem: Lincoln Pharmaceuticals Ltd Currently trading at Rs 27/ - EPS 4/- Target 45/- & 65/-
Buy Lincoln Pharmaceuticals Ltd at 27/- EPS 4/- Target 45/- & 65/-
Lincoln Pharmaceuticals Ltd. is another Natco Pharma Ltd (NATCO Pharma Ltd was recommended NATCO at 45/- 3 years back Now 357/- and touched 435/- means 10 times in 3 years; Like Natco Pharma Lincoln Pharma also move in Short term and Medium term TO 65/- & 150/-.)
Buy in for your Portfolio and get good returns in short term.
USFDA Approval News coming soon; its good Value Buy at this rate 27/- to 28/-.
Lincoln Pharmaceuticals Ltd Having Valuable Land in Ahmadabad nearly 7 Acres Value is nearly 21 Cr. Equity is just 11 Cr.
BUY LINCOLN PHARMACEUTICALS Ltd; doing Pharma Business; Stock Trading in BSE (Code : 531633) only . EPS 4/- Book Value 49/- PE just 7, Pharma Industry Avarage PE was 17; But this stock trading with PE just 7; If we take low PE 10 it will go 45/- ++; Equity 11 Cr; Every Year Dividend giving company from last 5 years onwards 12% means Rs. 1.2/- per share. Promoters Holding 39.78% Corporate Bodies 12.4% Public only 40% Target 65/- & 85/- within Short time.
Market may touch NIFTY 5,350 and BSE Sensex 17,500 SOON; FII's are hevily buying stage. Use this correction time for Buy LINCOLN PHARMACEUTICALS Ltd at 27/- Just Buy and hold 10 DAYS with good appreciation at 50% Profit because company having USFDA Approval Announcement and good EPS 4/- and good Book value at 49/- Good Dividend Paying company and company having strong fundamentals .
Recently Company allotted Preferential shares at 50/- So this stock is very valuable stock with risk free investment at 27/- . EPS 4/- Book value 49/- and Good Dividend paying Company.
Good Valuable Buy LINCOLN PHARMACEUTICALS Ltd. 10/- face Value Trading at 27/- with Target of 45/-. Risk is very very less because company stock was very Valuable because Book value at 49/ and Expecting EPS 6/- for 2012-2013. In Pharma sector average PE was 17, if you take this 17 Stock will come 90/- If u take minimum PE 10 It will come 65/- Equity 11cr. Just Buy and hold 1 month to 6 months with good appreciation at 100% Profit.
Lot of Accumulation is going on in BSE by Company circle people and operators Because Company engaged in Pharma and stock has good valuable at 31/- and less Equity 11 cr. Good Dividend Paying company. Check Delivery everyday 90% above.
LINCOLN PHARMACEUTICALS Ltd recorded total Revenues of 177 Crores and Net Profit 4.91 Cr for the year 2011-12 asn Expecting Revenue for 2012-13 is 230 Cr and net profit is 6.9 Cr based on this EPS will 6/- above because Expansion Income will add this year.
No Pharma Dividend Paying Company is trading in BSE or NSE with PE 6. Because Avarage PE fort Pharma is 17. But this Lincoln Pharma trading at 6 PE with EPS 4/- this year. Its very good future for this stock, No risk at 27/- Just Buy at 27/- Soon will touch 65/- & 75/-. Preferential Shares also given at 50/- recently. Its come Another NATCO PHARMA soonl NATCO I have Recommended at 45/- 3 years back now 357/- after tocuh 445/- measn 10 times return in 3 years, Same like NATCO this Lincoln Pharma will raise soon…
Share Holding:-
The Promoters holding 39.78%, Corporate bodies hold 12.4%, and Public only 40% .
Lincoln Pharmaceuticals is amongst the top world class quality oriented pharmaceutical producers, manufacturing and marketing various therapeutic molecules under WHO-GMP guidelines.Lincoln Pharmaceuticals Limited has pledged to serve the Health care segments, by providing Quality Pharmaceuticals at affordable prices.
Indian Pharmaceutical Industry is growing fast as far as export market is concerned, During last five years, there is a tremendous growth in the pharmaceutical industry. Lincoln Pharmaceuticals Limited has made successful achievement in overseas network for its formulations.
Lincoln Pharmaceuticals Ltd. has obtained drug registration for about 100 of its pharmaceuticals formulations in more than 10 African as well as in other countries too.
Kenya, Tanzania, Zimbabwe, Nigeria, Uganda, Sri Lanka, United Kingdom, Zambia, Republic of Yemen, Mauritius, Thailand, Ethiopia, Ghana.
Company View International Products
Company future planning is to expand business in following areas. We invite the interested parties from following countries who can represent our company and can explore business.
Carribean Islands,Central America,Latin America
Company plant facilities is certified by WHO GMP authorities as well as by ISO 9002. Company manufacture neutral label products for International Pharma Marketing companies. Company invite companies for contract manufacturing to produce their products.
See calls earned 50% to 300% for the Short term.
1) SE Investments given at 170/- Reached at 375/-
2) Techtran Poly given at 13/- Reached 21/-
3) Suraj Diamonds Given at 38/- reached 55/-
4) Bihar Tubes given at 57/- Reached at 105/-
5) Ponni Sugars given at 55/- Reached 175/-;
6) Pitti Laminations at 39/- Touched 99/-
7) Venus Power given at 8/- Reached 25/-
8) Comp-U-Learn given at 10/- reached 21/-
9) Natco Pharma given at 45/- Reached 445/-
10) Granules India given at 65/- Reached 150/- in very short Period.
11) IDL Industries given at 65/- Reached 99/-
12) Lanco Infra given at 10/- Reached 24/- But now 13/- Every down side at 10/- buy and hold.
13) Vikas WSP given at 15/- Reached 67/-
14) Usher Agro given at 27/- reached 115/-
Positive Points for this stock for Up moving:
1) Company is in Pharma Business; company Circle people and Operators are accumulating at current price. Because Company Stock Good Value at 27/- EPS 4/- PE 6 and Book Value at 49/- Equity is very small at 11Cr promoters Holding 39.78%
2) In Pharma Stocks Average PE was 17 But this stock trading with PE 6; If you take minimum 10 PE it will go 45/- minimum.
3) 12% Dividend Paying Company; September 19th is the Book Closure for Dividend.
4) Small Equity with good promoters Holding and having lot of Reserves and Good Book Value.
5) Lincoln Pharmaceuticals Ltd Having Valuable Land in Ahmadabad nearly 7 Acres Value is nearly 21 Cr. Equity is just 11 Cr.
6) USFDA Approval Announcement by next week.
7) Company having lot of Expansion Plans.
8) For this year Expected Revenue 230 Cr and Net Profit 6.9 Cr EPS 6.5/- PE 4.
9) Company Having good land bank near to Ahmedabad.
Happy Invest ……….. Good Fundamentals and will give good returns from 100% to 300% returns with short and medium terms and Long terms.
However, including stock-based compensation, payroll taxes and income tax adjustment, Facebook lost 8 cents per share compared with earnings of 11 cents per share in the year-ago quarter.
Quarter Details
Facebook's revenue jumped 32.3% year over year to $1.18 billion, slightly ahead of the Zacks Consensus Estimate of $1.15 billion. The year-over-year growth was driven by strong advertising revenue (84% of the total revenue) that climbed 28% year over year to $992.0 million. Facebook generated the rest of the revenue from payments & other fees in the quarter.
The strong upside in advertising revenues was primarily driven by an 18% increase in the number of ads delivered based on growth in the user base and an increase in average number of ads per page from the prior-year period.
However, strong growth in mobile user base continued to hurt Ad impressions, particularly in the US, where number of ads delivered decreased 2.0% year over year in the quarter.
Average price per ad increased 9.0% year over year, primarily aided by a 20% increase in CPMs in US due to the roll out of sponsored stories in news feed during the quarter for PC and mobile users. Price per ad growth was also strong in Asia and rest of the world, which fully offset a decline in Europe.
Monthly Active Users (MAU) improved 29% year over year to 955 million at the end of June 30, 2012. Mobile MAUs surged 67.0% year over year to 543 million at the end of quarter. During the same period, Daily Active Users (DAU) increased 32.0% year over year to 552 million.
Average revenue per user (ARPU) was $1.28 in the quarter, up double-digits in the US, Asia and rest of the world. ARPU grew 8.0% in Europe in the quarter.
However, this healthy growth in revenue and user base was partially offset by higher costs and operating expense in the quarter, particularly due to stock-based compensation, which totaled $1.3 billion in the quarter. Excluding this effect, operating expenses shot up 60.0% year over year to $669.0 million, driven by headcount growth and costs incurred related to infrastructure development.
Facebook's operating income increased 8.0% year over year to $515.0 million. However, including stock-based compensation and payroll-tax expenses related to share based compensation, the company reported an operating loss of $743.0 million.
Net Income was up 3.5% year over year to $295.0 million. However, including stock-based compensation, payroll-tax expenses related to share-based compensation and income tax adjustments, the company reported net loss of $157.0 million in the quarter.
Facebook ended the quarter with cash & cash equivalents of 10.19 billion. The company generated $242.0 million as cash flow from operations in the quarter.
Outlook
Facebook expects operating expenses to increase at a much faster rate compared to the second quarter in the second half of this year. The company expects steep rise in research & development expenses mainly due to continued investments in product development for mobile segment and infrastructure.
Our Take
We believe that Facebook has significant growth opportunities from increasing online advertising spending as compared to traditional formats. Facebook's massive user base and its ability to track personal details over time make it a formidable force in the online ad market. Facebook can use this massive database to help advertisers target relevant ads going forward.
However, increasing competition is the primary headwind for Facebook over the long term. Besides competition from Google+, Twitter, Orkut in its core markets, Facebook is also competing against small regional platforms, which not only limit its expansion opportunities but also hurt its profitability.
Facebook is facing significant competition in the display advertising market from Google ( GOOG ). Rising concerns over the effectiveness of Facebook ads as compared to Google's AdSense has been a headwind lately. As per eMarketer, Google is set to grab the #1 position in the display ad market by the end of 2013. We believe that Google's increasing popularity has the potential to limit Facebook's ad revenue growth going forward.
Further, Facebook's popularity is based on the engaging apps from its third-party developers, particularly Zynga ( ZNGA ). However, Zynga's narrow product portfolio has been primarily blamed for a waning interest in social games on the platform. Zynga's low-paying customer base and stiff competition from other established players are also hurting its top line. This does not bode well for Facebook, as the company earns the majority of its non-ad revenue from Zynga.
Apart from increasing competition, lack of visibility around mobile monetization remains a concern. Although Facebook has made a number of acquisitions (such as Snaptu, Instagram) to enhance its mobile offerings, we believe that lack of adequate ad coverage for the mobile platform will continue to hurt its revenue earning capacity going forward. Moreover, continued investments to expand mobile offerings are expected to hurt margins in the near term.
We remain Neutral over the long term (6-12 months). Currently, Facebook has a Zacks #3 Rank, which implies a Hold rating in the near term.
( Nasdaq )
July 2012
Supernus Pharmaceuticals Inc
MELA Sciences, Inc
Catalyst Pharmaceutical Partners, Inc
Somaxon Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus’s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Below is the Press Release of the news
Tuesday, 17 Jul 2012 04:05pm EDT
Somaxon Pharmaceuticals, Inc. announced that it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving Silenor 3 mg and 6 mg tablets. The settlement agreement with Mylan grants Mylan the exclusive right to begin selling an authorized generic version of Silenor (i.e., a generic version sold under Somaxon's New Drug Application) on January 1, 2020, or earlier under certain circumstances. Mylan's right to sell such an authorized generic product could extend for a period of as long as 360 days, and after such period Mylan will have the non-exclusive right to sell a generic version of Silenor under its Abbreviated New Drug Application. In connection with the settlement agreement, the parties also entered into a supply agreement under which Mylan has agreed to supply the Company with commercial quantities of Silenor 3 mg and 6 mg tablets. The settlement agreement with Par grants Par the right to begin selling a generic version of Silenor 180 days after the earlier of the date that a third party's generic version of Silenor is first sold in the United States under a license from Somaxon or a final court decision that the asserted patents are not infringed, invalid or unenforceable, or earlier under certain circumstances.
About Somaxon Pharmaceuticals, Inc.
Below is the Press Release
Catalyst Pharmaceutical Partners, Inc. today announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013.
After discussions with our collaborators, the National Institute on Drug Abuse (NIDA) and the Department of Veterans Affairs Cooperative Studies Program (VACSP), and our statistical and regulatory consultants, we have been able to work through the complexities of modifying our statistical analysis plan. This will enable us to report top-line trial results about four months earlier than previously expected.
"We are pleased that we will be able to report the top-line results of our CPP-109 Phase II(b) clinical trial sooner than expected," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "We are committed to bringing safe and effective breakthrough products for the treatment of cocaine addiction to the market as quickly as possible, and the earlier reporting of these data is consistent with that philosophy."
About the CPP-109 Phase II(b) Clinical Trial
The 24-week CPP-109 Phase II(b) clinical trial is randomized, double-blind and placebo-controlled in 207 patients recruited at 13 sites in the United States. It is designed to demonstrate that the rate of cocaine dependent subjects treated with CPP-109, who abstain from cocaine use in the last two weeks of the trial's treatment phase (weeks 8 and 9), will be higher than patients treated with placebo. Other outcomes include: i) reduction in cocaine use days; ii) increase in clean urines collected; and iii) improvements in other measures of subject well-being and cocaine craving.
About CPP-109 and Fast Track Status
CPP-109 is a GABA analog that is Catalyst's designation for vigabatrin. Catalyst licensed CPP-109 from Brookhaven National Laboratory for the treatment of cocaine and other addictions, and has been granted "Fast Track" status by the U.S. Food and Drug Administration (FDA) for cocaine addiction. Under the Federal Food, Drug, and Cosmetic Act, the FDA is directed to facilitate the development and expedite review of drugs and biologics intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Fast Track designation emphasizes communication between Catalyst and the FDA, and provides Catalyst benefits that may help to expedite the approval process. For example, Fast Track designation affords Catalyst the potential to submit a New Drug Application (NDA) for CPP-109 on a rolling or modular basis, allowing the FDA to review sections of the NDA in advance of receiving a full submission. The designation also means that Catalyst may have increased communications with the FDA regarding the design of its clinical studies, which may expedite the development and review of Catalyst's application for the approval of CPP-109 for cocaine addiction and may provide greater certainty overall in the regulatory pathway.
About Cocaine Addiction
According to the most recent Substance Abuse and Mental Health Services Administration (SAMHSA) survey, an estimated 1.5 million people, or 0.6% of the population aged 12 or over, had used cocaine in the month preceding the survey. Additionally, in 2010, approximately 637,000 people aged 12 or over had used cocaine for the first time within the preceding 12 months, an average of approximately 1,700 new users per day. In addition, approximately 699,000 patients received treatment for cocaine abuse in 2010.
Cocaine addiction is not only a U.S. health problem. In 2009, according to the United Nations Office on Drugs and Crime, there were 4.3 million -- 4.7 million users of cocaine between the ages of 15 and 64 across Europe who had used it within the past year. Catalyst believes that the direct and indirect costs of cocaine use are indicative of a global public health problem, representing a significant unmet medical need for which no adequate pharmaceutical therapies exist.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115. It is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. Both CPP-109 and CPP-115 have been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. Catalyst is also planning to evaluate CPP-109 for the treatment of other addictions. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to www.catalystpharma.com .
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-109 will be safe and effective for the treatment of addiction, whether the CPP-109 Phase II(b) clinical trial will be successful, whether any of the above-described benefits from having received Fast Track status from the FDA for CPP-109 will be realized by the Company, whether CPP-109 will ever be approved for commercialization, and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Multibagger Stock Pick.... Sumedha Fiscal Services Ltd ( BSE: 530419) at 17/- target 39/-.Buy Sumedha Fiscal Services Ltd trading in BSE (BSE CODE: 530419) at 17/- in B Group. Target 39/- for short term. Safe investment at 17/-. Its good worth stock.
Sumedha Fiscal Services Ltd DoinG financial services Company incorporated in the year 1989. Company Stock Face Value is 10/- Book Value is 29/-, Equity 6 Cr. Company having Good Assets and Reserves. Every Year dividend Paying company.
Sumedha Fiscal Services Ltd preferential issued at 31/- now trading at 17/- and EPS is 5.5/- reserves 23 cr per share 35/- Div 8% to 10% every year.
Stock : Sumedha Fiscal Services Ltd (BSE: 530419)
CMP : 17/-
Target : 39/- /- in Short term
Equity : 6 Cr
Promoters Holding : 43% ;
Face Value : 10/-
EPS : 5.5/- for 2011-12 and 2012-13 Expecting 9/- as per the Expansion Plans.
Book Value: 34/-
Every Year Dividend Paying company.
Dividend History :
2011 --- 8%; 2010 --- 8%; 2009 --- 8%;
Dividend Yielding per Year 4.9%.
Company Profile :-
Sumedha Fiscal Services was originally incorporated by Shrimati Savita Maheshwari and
Mr. Manoj Kumar Agarwal in the year 1989 and is a long established player in the Financial Services Industry.The Company offers a wide bouquet of services ranging from Corporate Finance, Equities,Commodities, Insurance, Wealth Advisory, Portfolio Management, Personal Finance,Currency Futures, Investment Banking and Institutional Broking Services. The company is a well known name in the small and medium enterprises group for its investment banking activities & commands approx 80% of its revenue from Investment banking alone.Investment serves clients which includes corporate/institutions, high net worth individuals and retail.
Segments which comes under that are:-
Stock Broking :-
Sumedha Fiscal is the member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited both for Cash and Derivatives segment. SFSL are also members in the Currency Futures Segment of the National Stock Exchange of India Limited, thus providing opportunities in hedging and trading of currency derivatives to our clientele. SFSL are also empanelled with most of the major Financial Institutions, Asset Management Companies, Banks and Corporate Groups. In addition, they have had the privilege of serving over many individuals, many of whom are in the High Net Worth (HNI) category.
Commodity Broking :-
SFSL Commodity Trading Pvt. Ltd. is a member of MCX Commodities.
Depository Services :-
Sumedha Fiscal provides depository services being Depository Limited (NSDL). Another Important source of Income is corporate services, segments which comes under that are :-
Merchant Banking
Sumedha Fiscal ventured into Merchant Banking and registered as a Category I Merchant Banker by SEBI, which means company is authorized as to carry on the business of merchants of banking in all its aspects, to act as manages to issue and offer, whether by way of public offer or otherwise of securities, to act as administrators or managers of any investments, trusts or exempts funds, provident, pension, gratuity and superannuation funds, charitable funds, unit trusts or consortium to act as trustees for bonds holders, debenture holders and for other purposes herein.Company has proven track record in Lead Management, Private Placement and Issue Advisory Services. Company has a great association with internationally reputed Merchant Bankers, coupled with some close relationships with various Investors and Intermediaries
which help them to make Public Issues a success. Sumedha has been associated with several prestigious Public Issues as Lead Manager, Co-Manager and Syndicate Member, Member of National Securities
Loan / Debt syndication
In Loan / Debt syndication company take care of the entire transaction which involves Capital Structuring, Feasibility Study, Project Appraisal and Sourcing Funds. In addition to it, company has long term association with Banks and Bankers which provide a special edge in arranging ecient negotiations and favourable terms, particularly in Loan Syndication. This makes a company competitive enough among its counterparts /peers
companies.
Financial Restructuring
Sumedha Fiscal also assist companies in restructuring their capital structure, negotiate with lenders for settlement of restructured loans, reschedule debt to lower interest costs and extend the repayment period. In extreme cases company also arrange Mergers and Takeovers of stressed Companies. This is the major revenue generating at the time of boom as well as slowdown period.
Portfolio Resolution of Stressed Assets
Company is also into Portfolio Resolution of Stressed Assets. An increased emphasis by Reserve Bank of India on improving asset quality and capital adequacy is causing a number of Banks and Institutions to focus on Non Performing Assets (NPA) Management. Sumedha Fiscal has requisite experience; specialized skill sets and focused approach to facilitate resolution and settlement of loans. Company is empanelled with major Banks and Financial Institutions as Recovery Agent.
Mergers & Takeovers
Sumedha Fiscal also assist companies in restructuring their capital structure, negotiate with lenders for settlement of restructured loans, reschedule debt to lower interest costs and extend the repayment period. In extreme cases company also arrange Mergers and Takeovers of stressed Companies. This is the major revenue generating at the time of boom as well as slowdown period.
Portfolio Resolution of Stressed Assets
Company is also into Portfolio Resolution of Stressed Assets. An increased emphasis by Reserve Bank of India on improving asset quality and capital adequacy is causing a number of Banks and Institutions to focus on Non Performing Assets (NPA) Management. Sumedha Fiscal has requisite experience; specialized skill sets and focused approach to facilitate resolution and settlement of loans. Company is empanelled with major Banks and Financial Institutions as Recovery Agent.
Mergers & Takeovers
Company core competence includes value oriented research and identifying business partners, suggesting economically viable projects and arranging technical and financial collaborations. Along with our International Aliates, company arrange global, technical and financial collaborations and provide assistance in preparing necessary project documentation and obtaining statutory approvals for such projects.
Equity Placements
Company also caters into equity placement which helps clients in Syndication and arrangement of Private Equity and Venture Capital Financing. It also arranges Equity Financing for Corporate and Entrepreneurs for Seed Capital, Early Stage and Late Stage Financing.
Subsidiaries in commodities are:-
SFSL Risk Management Services (P) Ltd. SFSL Commodity Trading (P) Limited is the subsidiary company of SFSL.
Subsidiaries in commodities are:-
SFSL Risk Management Services (P) Ltd. SFSL Commodity Trading (P) Limited is the subsidiary company of SFSL.
SFSL Insurance Advisory Services (P) Ltd.
Seasoft Solutions Pvt. Ltd.
Capita Finance Services (P) Ltd.
Financial Highlights
Market Cap: [Rs.Cr.] 11 crs |
Face Value: [Rs.] 10
P/BV (x) 0.66
ROCE (%) 31.3
EPS 5.9
Dividend Yield (%) 4.1
RONW (%) 23.7
EV/ EVBIDTA (x) 1.88
So there is a long way to go. Investors with faith in Sumedha Fiscal Services Limited
management and having patience will definitely earn a lot.
Possitive Points for this stock for Up moving:
1) Company doing very good with EPS 5.45/- PE only 3 Available very cheep at 17/-
2) Equity is very small at 6 Crores..
3) Dividend Paying Company.
4) Preferential Issued at 31/- to promoters.
5) Expansion Plans going on, This year Profit may zoom and EPS 9/-+++ .
6) Accumulating by Operators and Mutual Funds.
7) Its very worthy stock at 17/- to accumulate, Every one hodl 1,000 shares will get double in 1 month.
Enter current price at 17/- Short term Target 39/- Strong Fundamentals. Just Buy at 17/- get 200% to 500% Profit.
Happy Investing...
Seasoft Solutions Pvt. Ltd.
Capita Finance Services (P) Ltd.
Financial Highlights
Market Cap: [Rs.Cr.] 11 crs |
Face Value: [Rs.] 10
P/BV (x) 0.66
ROCE (%) 31.3
EPS 5.9
Dividend Yield (%) 4.1
RONW (%) 23.7
EV/ EVBIDTA (x) 1.88
So there is a long way to go. Investors with faith in Sumedha Fiscal Services Limited
management and having patience will definitely earn a lot.
Possitive Points for this stock for Up moving:
1) Company doing very good with EPS 5.45/- PE only 3 Available very cheep at 17/-
2) Equity is very small at 6 Crores..
3) Dividend Paying Company.
4) Preferential Issued at 31/- to promoters.
5) Expansion Plans going on, This year Profit may zoom and EPS 9/-+++ .
6) Accumulating by Operators and Mutual Funds.
7) Its very worthy stock at 17/- to accumulate, Every one hodl 1,000 shares will get double in 1 month.
Enter current price at 17/- Short term Target 39/- Strong Fundamentals. Just Buy at 17/- get 200% to 500% Profit.
Happy Investing...
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment of cancer and viral infections. As of April 30, 2011, the Company had three Phase II clinical programs, including two oncology programs, as well as a hepatitis C virus (HCV) program. Peregrine’s pipeline of investigational monoclonal antibodies is based on two technology platforms, including phosphatidylserine (PS)-targeting antibodies and deoxyribonucleic acid (DNA)/histone-targeting antibodies. Bavituximab is its PS-targeting antibody. Cotara is the Company’s DNA/histone-targeting antibody-based on its Tumor Necrosis Therapy (TNT) technology platform. Peregrine’s wholly owned biomanufacturing subsidiary is Avid Bioservices, Inc., which provides integrated cGMP commercial and clinical manufacturing services for Peregrine and third-party clients.
About Chelsea Therapeutics International Ltd
Company has announced an enrollment for Phase II/Phase III trials of gevokizumab to treat interleukin-1 beta-mediated inflammatory diseases
Press release read below
It has opened enrollment in two clinical trials to determine gevokizumab's potential to treat interleukin-1 beta-mediated inflammatory diseases. The first trial is XOMA's global Phase 3 study investigating the ability of gevokizumab to reduce the signs and symptoms, including vitreous haze, in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The second trial is a Phase 2 study to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with erosive osteoarthritis of the hand. Patients currently are being screened in both trials.
In this study, titled A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis, the Company intends to enroll patients with active non-infectious intermediate, posterior, or pan-uveitis with a vitreous haze score equal to or greater than 2+ on the Standardization of Uveitis Nomenclature (SUN) / National Eye Institute (NEI) scale in at least one eye. They will be randomized to receive either one of two doses of gevokizumab or placebo. The study's primary endpoint is the proportion of patients demonstrating a significant reduction in vitreous haze score on Day 56. The study also will assess the effect of gevokizumab on additional endpoints, including response rates at other time points and changes from baseline in visual acuity.
Paul Rubin, M.D., XOMA's Senior Vice President of Research and Development and Chief Medical Officer, stated, "As preclinical and clinical data have shown that IL-1 beta is an important contributor to the inflammation seen in uveitis, we believe gevokizumab's ability to potently inhibit IL-1 beta signaling could be relevant in controlling this inflammation, as well as the inflammation associated with other conditions. Because of this, we established a proof-of-concept program in November 2011 to lead us to additional indications for this antibody. Included in this program is the ongoing trial in moderate to severe acne vulgaris from which we anticipate top-line data by year end. Today, we opened enrollment in the second POC indication, erosive osteoarthritis of the hand, which we believe will complete enrollment sometime around the end of 2012."
XOMA's Phase 2 proof-of-concept study of gevokizumab in active inflammatory, erosive osteoarthritis of the hand is designed to enroll approximately 90 patients who will be randomized to receive gevokizumab or placebo. The study is designed and powered to detect a significant improvement from baseline versus placebo in the mean Australian/Canadian Hand Osteoarthritis Index (AUSCAN™) pain score in the target hand at three months. The study also will capture multiple outcome measures including pain, stiffness, physical function, radiographic and MRI changes, as well as changes in C-reactive protein and concomitant acetaminophen use.
About XOMA corporation:
XOMA Corporation (XOMA), formerly XOMA Ltd., discovers and develops antibody-based therapeutics. XOMA’s drug candidate gevokizumab is an antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Its XOMA 3AB is a biodefense anti-botulism product candidate consists of a combination of antibodies, was developed through funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the United Sates National Institutes of Health (NIH). In June 2011, it discovery of two classes of human monoclonal antibodies, XOMA Metabolic Activating and Sensitizing (XMetA and XMetS), On January 17, 2012, it announced that it had acquired the United Sates rights to the perindopril franchise from Servier. The agreement includes ACEON, a marketed angiotensin converting enzyme (ACE) inhibitor, and a portfolio of three fixed-dose combination product candidates where perindopril is combined with another active ingredient(s), such as a calcium channel blocker.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. RX-5902 is a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis. The phosphorylated form of p68 RNA helicase is only present in cancer cells and is absent in normal cells.
“RX-5902 is an exciting first-in-class p68 RNA helicase inhibitor that has considerable commercial potential,” said Rick Soni, President of Rexahn. “Pre-clinical studies have shown that RX-5902 exhibits very potent anti-tumor activity in various cancers including melanoma, renal, ovarian and pancreatic. Additional studies suggest that RX-5902 is effective in drug-resistant cancer cells and is synergistic when combined with current cancer drugs.”
About Rexahn Pharmaceuticals, Inc.
Hidden gem " Rama pulp & papers limited” (BSE code: 502587) AT 11/- target of 19/- & 35/-
STOCK : RAMA PULP & PAPERS LIMITED (BSE CODE: 502587)
CMP : 11/-
Target : 19/- to 35/- in Short term and Medium terms;
Equity : 11 Cr
Reserves : 23.43 Cr (Per share Rs. 22/-).
Promoters Holding : 19.31% ;
Body Corporate : 35%;
Public Only 43%
Face Value : 10/-
EPS : 2.35/- for 2011-12 and 2012-13 Expecting 4/- as per the Order Book.
Book Value: 34/-
Every Year Dividend Paying company.
Dividend History :
2011 --- 5%; 2010 --- 5%; 2009 --- 5%; 2008 --- 5%; 2007 --- 10%
Dividend Yielding per Year 4.55%.
RAMA PULP & PAPERS LIMITED Having Good Land Bank and Valuable Assets.
RAMA PULP & PAPERS LIMITED Stock Will go 19/- to 35/- range in Short term and Medium Term., Like SE Investment (Call Given at 175/- Now including Bonus and Stock split 1250/-) and Bihar Tubes Ltd (Call Given at 57/- Now 165/-).
For 2011-12 Year Net Income of 70.9 Cr and Net Profit was 2.528 Cr EPS 2.35/-.
For 2012-13 Full Year Estimating Net Income of 97 Cr and Net Profit of 4 Cr As per this EPS was 4/- above. Stock Trading at 11/- PE just 3 Industry PE is 11. As per this Stock will zoom to 35/- levels in 6 Months to 1 Year Time.
Given its low debt-equity ratio of 0.35:1, a dividend yield of 4.47% and a healthy ROE of 32% , the stock`s valuations appear to be quite attractive.
Rama Pulp & Papers Limited (RPPL) is a certified ISO 9001-2000 Company, engaged in manufacturing various types of papers mainly cultural and specialty grades.
Rama Pulp preservation of environment is an objective. The products are manufactured from 100% recycled indigenous and imported waste paper, thereby preserving the environment. Company has given extra focus on its effluent treatment and is successful to keep clean environment and almost zero discharge mill.
RPPL has firmly positioned itself among prominent paper manufacturing groups based in India. Rama Pulp and paper is a midsized player in the Indian paper industry. The company currently operates with a capacity of 21,000 tpa with the capability to manufacture various paper varieties like writing-printing and carbon base paper, poster and wrapping paper, napken grade tissue paper etc. RPPL is expanding its capacity to 30,000 MT's. p.a. The company has a strong distribution network that enables it to market its products in various regions. Today RPPL has grown from strength to strength with its diversified product mix and strategic marketing plan.
With further expansion programs on hand, RPPL is now looking ahead to meet the emerging challenges both in domestic as well as overseas market. Keeping in view to take the company to the next level, company is planning to acquire an existing Industrial Chemical Unit to produce various industrial grades of chemicals, especially Sulfonated products like Sulfur Dioxide, Sulfur Trioxide etc. This new venture will give the company a new lease of life. As the paper industry requires lot of steam and power, the high pressure steam being vented out of the manufacturing process of these chemicals can be used for running the steam based power plant and then the extracted steam will be used for manufacturing of paper. Hence, the paper mill will self sufficient for its requirement of energy like steam and power. The will make the company very high on its bottom line. RPPL has a strong product mix that would enable it to cater to the demands of various customer segments.
The new value added products introduced by the company are well accepted by the dealers as well as the end users, which ultimately gave a forward thrust to the company to emerge as a key player in this segment. The Carbon base paper being manufactured by the company has a market share of more than 50%, which places the company among the top players in this segment. The company is exporting its products to a very reputed chain of departmental stores like WALLMART and its specialty grade paper is very well accepted globally. The demand of paper as a whole is in a growing spree. The demand of paper is directly linked to the literacy of a particular country and in India, with implementation of educational policy, the literacy rate is growing and paper consumption is also in upward. Therefore, a steady growth in the demand of paper, especially writing printing, newsprint etc., is expected.
RPPL is expected to register robust growth in revenues and earnings going forward. It is currently quoting at compelling valuations of 3x FY12E earnings. Capacity expansion and growing demand for paper from various segments like education, industrial and specialty, in addition to its inorganic growth in Sulfonated chemicals will drive revenue and earnings growth for RPPL. The stock has potential to deliver handsome returns to the investors over a period of next one year. Investors can enter into the stock at current level considering the huge growth potential, which would enable investors to earn a healthy return on their investment.
Strength of the Company
Dividend Yielding per Year 4.55%.
RAMA PULP & PAPERS LIMITED Having Good Land Bank and Valuable Assets.
RAMA PULP & PAPERS LIMITED Stock Will go 19/- to 35/- range in Short term and Medium Term., Like SE Investment (Call Given at 175/- Now including Bonus and Stock split 1250/-) and Bihar Tubes Ltd (Call Given at 57/- Now 165/-).
For 2011-12 Year Net Income of 70.9 Cr and Net Profit was 2.528 Cr EPS 2.35/-.
For 2012-13 Full Year Estimating Net Income of 97 Cr and Net Profit of 4 Cr As per this EPS was 4/- above. Stock Trading at 11/- PE just 3 Industry PE is 11. As per this Stock will zoom to 35/- levels in 6 Months to 1 Year Time.
Given its low debt-equity ratio of 0.35:1, a dividend yield of 4.47% and a healthy ROE of 32% , the stock`s valuations appear to be quite attractive.
Rama Pulp & Papers Limited (RPPL) is a certified ISO 9001-2000 Company, engaged in manufacturing various types of papers mainly cultural and specialty grades.
Rama Pulp preservation of environment is an objective. The products are manufactured from 100% recycled indigenous and imported waste paper, thereby preserving the environment. Company has given extra focus on its effluent treatment and is successful to keep clean environment and almost zero discharge mill.
RPPL has firmly positioned itself among prominent paper manufacturing groups based in India. Rama Pulp and paper is a midsized player in the Indian paper industry. The company currently operates with a capacity of 21,000 tpa with the capability to manufacture various paper varieties like writing-printing and carbon base paper, poster and wrapping paper, napken grade tissue paper etc. RPPL is expanding its capacity to 30,000 MT's. p.a. The company has a strong distribution network that enables it to market its products in various regions. Today RPPL has grown from strength to strength with its diversified product mix and strategic marketing plan.
With further expansion programs on hand, RPPL is now looking ahead to meet the emerging challenges both in domestic as well as overseas market. Keeping in view to take the company to the next level, company is planning to acquire an existing Industrial Chemical Unit to produce various industrial grades of chemicals, especially Sulfonated products like Sulfur Dioxide, Sulfur Trioxide etc. This new venture will give the company a new lease of life. As the paper industry requires lot of steam and power, the high pressure steam being vented out of the manufacturing process of these chemicals can be used for running the steam based power plant and then the extracted steam will be used for manufacturing of paper. Hence, the paper mill will self sufficient for its requirement of energy like steam and power. The will make the company very high on its bottom line. RPPL has a strong product mix that would enable it to cater to the demands of various customer segments.
The new value added products introduced by the company are well accepted by the dealers as well as the end users, which ultimately gave a forward thrust to the company to emerge as a key player in this segment. The Carbon base paper being manufactured by the company has a market share of more than 50%, which places the company among the top players in this segment. The company is exporting its products to a very reputed chain of departmental stores like WALLMART and its specialty grade paper is very well accepted globally. The demand of paper as a whole is in a growing spree. The demand of paper is directly linked to the literacy of a particular country and in India, with implementation of educational policy, the literacy rate is growing and paper consumption is also in upward. Therefore, a steady growth in the demand of paper, especially writing printing, newsprint etc., is expected.
RPPL is expected to register robust growth in revenues and earnings going forward. It is currently quoting at compelling valuations of 3x FY12E earnings. Capacity expansion and growing demand for paper from various segments like education, industrial and specialty, in addition to its inorganic growth in Sulfonated chemicals will drive revenue and earnings growth for RPPL. The stock has potential to deliver handsome returns to the investors over a period of next one year. Investors can enter into the stock at current level considering the huge growth potential, which would enable investors to earn a healthy return on their investment.
Strength of the Company
Company is strategically located in the Industrial Area at Vapi, Gujarat with modern infrastructure & facilities.
Flexibility of manufacturing Industrial and Tailor made paper in 16 Gsm. to 180 Gsm range.
Industrial grade products qualities at par with global standards with Substantial market share.
Capacity to produce value added and specialty grade papers.
Excellent distribution network.
Dedicated and competent technical /marketing team.
Rama Pulp has got an elaborate R&D set-up, focusing on the individual needs of our customers and providing them with specific solutions to their particular needs. We attempt to understand the processes of our customers, as well as their end usages and to supply them with specialized qualities which best fulfill their needs.
Valuation:
The company does seem undervalued significantly based on even conservative measures.
Market Cap: 12 Crores.
Reserves : 23.43 Cr means per share 22/- Now trading at 11/- Almost 50% discount.
Sales: 70 Crores.
Profits: 2.528 Crores.
Last 3 year average profits: 4 Crores.
P/E: 3.xx.
Avarage PE for this Industry is 11/-.
As per this stock Valuation is up to 35/-.
RAMA PULP & PAPERS LIMITED having Lot Expansion Plans in Fututre. It's a Multibagger stock. Just buy and hold 1 year will get 5 times Return like NATCO Pharma (Call given in 2009 at 40/- levels Now 450/-) and SE Investments Ltd (This Stock I have Recommended at 175/- levels after that reached 1200/- levels including Bonus and Split).
Positive Points for this stock for Up moving:
1) Company is in Paper Business; company Circle people and Operators are accumulating at current price. Because Company Stock Good Value at 11/- Good Profit making company and Book Value at 34/- and Good dividend paying company.
2) Equity is very small at 11 Cr
3) Company Having Good reserves at 23.487 Cr means per share 22/- Stock Trading at 11/- So 50% discount with reserves.
4) Good Profit Making Company for 20011-12 EPS 2.528/- Annualized and Expecting EPS for full year 2012-13 is above 4/-because Good Order Book.
5) Company having Good Book Value 34- and Good Land Bank and Good Assets.
6) Good Dividend Paying company every year 5% to 10%, So Dividend yielding is 4.56%.
Ampio Pharmaceuticals ( NASDAQ: AMPE ) stock jumped more than 30% to $5.16 and touched an intraday high of $5.50. There was not specific announcements from the company regarding any developments. Up move might last if there might be an insider news or announcements, that might come later today or tomorrow. Traders should follow it closely for a momentum trade. Last development news from company was on June 11 2012, when company has announced a positive clinical trial data for its drug Optina used in Diabetic macular edema. Read belowAmpio Pharmaceuticals Inc announced that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada. The primary end point for efficacy was central subfield retinal thickness as measured by Optical Coherence Tomography (OCT) and reported in microns. The study was double masked and included 32 patients with moderate to severe diabetic macular edema (range 316-707microns) that were treated orally with either placebo or one of three doses of Optina. Central retinal thickness and retinal volumes were measured at baseline and at four and 12 weeks of treatment. The results confirm a significant interaction between the patient's body mass index (BMI) and efficacy at the different doses of Optina. For higher BMI (BMI=35) patients, higher doses of Optina were more effective and for lower BMI (BMI=26) patients, lower doses were more effective. The improvement of efficacy by adjusting the dose to the BMI is in agreement with both in vitro data as well as with the known strongly lipophilic nature of Optina. At one of the low doses, regardless of BMI, there was a reduction of the subfield central retinal thickness of approximately 20% at four and at 12 weeks, which was statistically significant from placebo for the higher BMI group (p = 0.01).
Following the earnings announcement, the BlackBerry maker's shares dropped sharply after earlier being halted ahead of the report.
The company posted a first-quarter loss excluding items of 37 cents per share, down from a quarterly profit of $1.33 a share in the year-earlier period.
Its adjusted net loss was $192 million, or 37 cents a share, down from net income of $695 million, or $1.33 a share, last year.
Revenue plunged 43 percent to $2.8 billion, from $4.91 billion a year ago.
Analysts had expected the company to report a quarterly loss excluding items of 3 cents a share on $3.10 billion in revenue, according to a consensus estimate from Thomson Reuters.
Following the earnings announcement, CEO Thorsten Heins said the company will aggressively drive sales of BlackBerry 7 devices and launch a new PlayBook tablet soon but expects a loss in the current quarter.
Last month, the company warned that it would report its second consecutive operating loss this quarter. Before the warning, analysts had been expecting a profit of 42 cents per share, according to Thomson Reuters.
The loss is the latest in a string of dismal messages for the once-dominant BlackBerry maker that has seen its smartphone market share be eroded byApple's iPhone and devices running Google's Android operating software.
In May the company hired JPMorgan and RBC Capital to look at its strategic options and has announced impending layoffs as the company's shares continue their slide downward.
